Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of immunoregulatory mixture and its application

A technology of immune regulation and mixture, which is applied in the direction of drug combination, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve the problems of high toxicity, side effects, difficulties, unfavorable saving of blood sources and medical expenses of immunosuppressants, and achieve saving Blood source, less toxic and side effects

Active Publication Date: 2021-03-23
陕西医大血友病研究院
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The average success rate of antibody clearance is 70% for HA and 25% for HB, and can be complicated by allergic reactions and irreversible kidney damage. The recurrence rates in 1 year, 3 years, and 5 years are 12.8% and 32.5%, respectively, indicating that ITI therapy still has many defects
As far as blood sources are concerned, there are about 80,000 to 100,000 hemophiliacs in the country, and the concomitant rate of inhibitors is 20 to 30%. About 18 million tubes of human coagulation factor VIII are needed every year, which requires a huge amount of blood and funds, which is not conducive to saving blood sources and Medical expenses
[0004] For the treatment of acquired hemophilia complicated with inhibitors, prednisone 1-1.5 mg (kg.d) is the first choice at present, and cyclophosphamide 1-2 mg / (kg.d) and azathioprine 100 mg / d can be combined for treatment ineffective ~200mg / d, cyclosporine 2mg / (kg.d)~5mg / (kg.d), the course of treatment is 3~12 weeks, and the effective rate is 50%. Obesity, femoral head necrosis and other eight major side effects
Easy to relapse after drug withdrawal also brings difficulties to treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of immunoregulatory mixture and its application
  • A kind of immunoregulatory mixture and its application
  • A kind of immunoregulatory mixture and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0034] This example provides an immunomodulatory mixture, which is prepared by decocting 200ml of the following medicines: Radix Astragali: 30g, Ginseng: 10g, Atractylodes Rhizoma: 15g, Turtle Shell: 15g, Ligustrum lucidum: 30g, Angelica: 12g, Paeoniae Rubra : 12g, paeonol: 12g, raw rehmannia: 15g, flavescens: 6g, rhubarb: 10g, roasted licorice: 6g.

[0035]The preparation method of the above-mentioned immunomodulatory mixture is to soak the medicine in the formula with an appropriate amount of water for more than 2 hours, then boil it on a high fire and then change it to a low heat and boil it for 1 hour. After the medicine liquid is concentrated to 200ml, pour it out, and then add an appropriate amount of water and repeat the boil. Once, pour out the medicinal solution after it is concentrated to 200ml, discard the medicinal residues, combine and mix the medicinal solutions twice, divide into 2 bags, each bag is 200ml.

[0036] Brief Introduction of Drugs in Immunomodulatory...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an immunomodulation mixture which is prepared by decocting the following medicines with water: 30g radix astragali preparata, 10g ginseng, 15g bighead atractylodes rhizome, 15gturtle shell, 30g glossy privet fruit, 12g Chinese angelica, 12g radix paeoniae rubra, 12g cortex moutan, 15g radix rehmanniae recen, 6g radix sophorae flavescentis, 10g dock root and 6g radix glycyrrhizae preparata. The prepared immunomodulation mixture is used for a combination medicine for treating a congenital and acquired hemophilia inhibitor and administrated in two stages, namely remissioninduction (28 days) and consolidation therapy; the combination medicine is used for treating 26 patients with the congenital and acquired hemophilia inhibitor; and reexamination after treatment for 28 days shows that a complete remission rate is 96.15%, a partial remission rate is 3.85%, and a total effective rate is 100%. After follow-up for 1-3 years, only one patient experiences recurrence; the other 25 patients are alleviated continuously; the medical cost burden of the patients and the country can be reduced greatly; and a new medication is provided for treating the congenital and acquired hemophilia inhibitor.

Description

technical field [0001] The invention relates to a medicine for treating hemophilia, in particular to an immunoregulatory mixture and its application. Background technique [0002] Hemophilia (Hemophilia) is a group of bleeding disorders that are the most common among genetic diseases, and its clinical manifestations are characterized by three highs (high bleeding rate, high mortality rate, and high disability rate) [1-2] . For half a century, modern medicine has made great progress in the treatment of hemophilia hemorrhage with the replacement therapy of coagulation factor VIII / IX (FVIII / FIX). FⅨ allotype and self-specific inhibitors (FⅧ / FⅨ antibody) are produced, inhibit and inactivate 98% of FⅧ / FⅨ activity (FⅧ / FIX: C), resulting in ineffective coagulation factor replacement therapy, aggravating bleeding, death and disability [3-4] . The production of inhibitors is the main reason for the ineffectiveness of current alternative therapies, and it is a world challenge that ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/804A61K45/06A61P7/04A61P37/02A61K35/586
CPCA61K35/586A61K36/232A61K36/258A61K36/284A61K36/481A61K36/484A61K36/489A61K36/638A61K36/65A61K36/70A61K36/71A61K36/804A61K45/06A61K2236/331A61K2236/39A61K2236/51A61K2236/53A61K2300/00
Inventor 刘陕西刘义国
Owner 陕西医大血友病研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products